CYP2B6 Polymorphisms in Ketamine
Status: | Completed |
---|---|
Conditions: | Healthy Studies |
Therapuetic Areas: | Other |
Healthy: | No |
Age Range: | 18 - 50 |
Updated: | 5/20/2018 |
Start Date: | November 2013 |
End Date: | May 2017 |
Role of CYP2B6 Polymorphisms in Ketamine Metabolism and Clearance
This research study will determine if genetic variation in CYP2B6 affects how the body
metabolizes ketamine.
metabolizes ketamine.
Inclusion Criteria:
1. 18-50 yr old
2. CYP2B6*1/*1, CYP2B6*1/*6 or CYP2B6*6/*6 genotype (see table) (Note: subjects of other
rare genotype but with one or more 516G>T, 785A>G, 983T>C or 1459C>T polymorphism may
be enrolled at PI's discretion)
3. Good general health with no remarkable medical conditions
4. BMI <33
5. Provided informed consent
Exclusion Criteria:
1. Known history of liver or kidney disease
2. Use of prescription or non prescription medications, herbals, foods or chemicals known
to be metabolized by or affecting CYP2B6
3. Females who are pregnant or nursing
4. Known history of drug or alcohol addiction (prior or present addiction or treatment
for addiction)
5. Direct physical access to and routine handling of addicting drugs in the regular
course of duty (this is a routine exclusion from studies of drugs with addiction
potential)
We found this trial at
1
site
660 S Euclid Ave
Saint Louis, Missouri 63110
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
Click here to add this to my saved trials